PURPOSE: This study was carried out to determine the biodistribution profiles and tumor localization potential of poly(ethylene oxide) (PEO)-modified poly(beta-amino ester) (PbAE) as a novel, pH-sensitive biodegradable polymeric nanoparticulate system for tumor-targeted drug delivery. METHODS: The biodistribution studies of PEO-modified PbAE and PEO-modified poly(epsilon-caprolactone) (PCL), a non-pH-sensitive polymer, nanoparticle systems were carried out in normal mice using 111indium-oxine [111In] as a lipophilic radiolabel encapsulated within the polymeric matrix, and the distribution of the nanoparticles was studied in plasma and all the vital organs following intravenous administration. Solid tumors were developed on nude mice using human ovarian carcinoma xenograft (SKOV-3) and the change in concentrations of tritium [3H]-labeled paclitaxel encapsulated in polymeric nanoparticles was examined in blood, tumor mass, and liver. RESULTS: Study in normal mice with a gamma-emitting isotope [111In] provided a thorough biodistribution analysis of the PEO-modified nanoparticulate carrier systems, whereas 3H-paclitaxel was useful to understand the change in concentration and tumor localization of anticancer compound directly in major sites of distribution. Both PEO-PbAE and PEO-PCL nanoparticles showed long systemic circulating properties by virtue of surface modification with PEO-containing triblock block copolymer (Pluronic stabilizer. Although the PCL nanoparticles showed higher uptake by the reticuloendothelial system, the PbAE nanoparticles effectively delivered the encapsulated payload into the tumor mass. CONCLUSIONS: PEO-modified PbAE nanoparticles showed considerable passive tumor targeting potential in early stages of biodistribution via the enhanced permeation and retention (EPR) mechanism. This prompts a detailed biodistribution profiling of the nanocarrier for prolonged periods to provide conclusive evidence for superiority of the delivery system.
PURPOSE: This study was carried out to determine the biodistribution profiles and tumor localization potential of poly(ethylene oxide) (PEO)-modified poly(beta-amino ester) (PbAE) as a novel, pH-sensitive biodegradable polymeric nanoparticulate system for tumor-targeted drug delivery. METHODS: The biodistribution studies of PEO-modified PbAE and PEO-modified poly(epsilon-caprolactone) (PCL), a non-pH-sensitive polymer, nanoparticle systems were carried out in normal mice using 111indium-oxine [111In] as a lipophilic radiolabel encapsulated within the polymeric matrix, and the distribution of the nanoparticles was studied in plasma and all the vital organs following intravenous administration. Solid tumors were developed on nude mice using humanovarian carcinoma xenograft (SKOV-3) and the change in concentrations of tritium [3H]-labeled paclitaxel encapsulated in polymeric nanoparticles was examined in blood, tumor mass, and liver. RESULTS: Study in normal mice with a gamma-emitting isotope [111In] provided a thorough biodistribution analysis of the PEO-modified nanoparticulate carrier systems, whereas 3H-paclitaxel was useful to understand the change in concentration and tumor localization of anticancer compound directly in major sites of distribution. Both PEO-PbAE and PEO-PCL nanoparticles showed long systemic circulating properties by virtue of surface modification with PEO-containing triblock block copolymer (Pluronic stabilizer. Although the PCL nanoparticles showed higher uptake by the reticuloendothelial system, the PbAE nanoparticles effectively delivered the encapsulated payload into the tumor mass. CONCLUSIONS:PEO-modified PbAE nanoparticles showed considerable passive tumor targeting potential in early stages of biodistribution via the enhanced permeation and retention (EPR) mechanism. This prompts a detailed biodistribution profiling of the nanocarrier for prolonged periods to provide conclusive evidence for superiority of the delivery system.
Authors: M C Varela ; M Guzmán; J Molpeceres; M del Rosario Aberturas; D Rodríguez-Puyol; M Rodríguez-Puyol Journal: Eur J Pharm Sci Date: 2001-02 Impact factor: 4.384
Authors: Nazila Kamaly; Zeyu Xiao; Pedro M Valencia; Aleksandar F Radovic-Moreno; Omid C Farokhzad Journal: Chem Soc Rev Date: 2012-03-05 Impact factor: 54.564
Authors: Zhi Yang; Jeffrey Leon; Mike Martin; John W Harder; Rui Zhang; Dong Liang; Wei Lu; Mei Tian; Juri G Gelovani; Alex Qiao; Chun Li Journal: Nanotechnology Date: 2009-03-31 Impact factor: 3.874
Authors: Yan Geng; Paul Dalhaimer; Shenshen Cai; Richard Tsai; Manorama Tewari; Tamara Minko; Dennis E Discher Journal: Nat Nanotechnol Date: 2007-03-25 Impact factor: 39.213
Authors: Lars Stelter; Jens G Pinkernelle; Roger Michel; Ruth Schwartländer; Nathanael Raschzok; Mehmet H Morgul; Martin Koch; Timm Denecke; Juri Ruf; Hans Bäumler; Andreas Jordan; Bernd Hamm; Igor M Sauer; Ulf Teichgräber Journal: Mol Imaging Biol Date: 2009-07-07 Impact factor: 3.488
Authors: Sean M Hartig; Rachel R Greene; Gianluca Carlesso; James N Higginbotham; Wasif N Khan; Ales Prokop; Jeffrey M Davidson Journal: Biomaterials Date: 2007-05-03 Impact factor: 12.479